Literature DB >> 10203776

Large-scale production of pharmaceutical-grade plasmid DNA for gene therapy: problems and bottlenecks.

D M Prazeres1, G N Ferreira, G A Monteiro, C L Cooney, J M Cabral.   

Abstract

Gene therapy is a promising process for the prevention, treatment and cure of diseases such as cancer, acquired immunodeficiency syndrome (AIDS) and cystic fibrosis. One of the methods used to administer therapeutic genes is the direct injection of naked or lipid-coated plasmid DNA, but this requires considerable amounts of plasmid DNA. There are several problems and bottlenecks associated with the design and operation of large-scale processes for the production of pharmaceutical-grade plasmid DNA for gene therapy.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10203776     DOI: 10.1016/s0167-7799(98)01291-8

Source DB:  PubMed          Journal:  Trends Biotechnol        ISSN: 0167-7799            Impact factor:   19.536


  20 in total

1.  Gene transfer in vitro and in vivo by cationic lipids is not significantly affected by levels of supercoiling of a reporter plasmid.

Authors:  D Bergan; T Galbraith; D L Sloane
Journal:  Pharm Res       Date:  2000-08       Impact factor: 4.200

2.  Non-GMP plasmid production for transient transfection in bioreactors.

Authors:  G Schmid; E J Schlaeger; B Wipf
Journal:  Cytotechnology       Date:  2001-05       Impact factor: 2.058

3.  On the stability of plasmid DNA vectors during cell culture and purification.

Authors:  S S Freitas; A R Azzoni; J A L Santos; G A Monteiro; D M F Prazeres
Journal:  Mol Biotechnol       Date:  2007-06       Impact factor: 2.695

4.  DNA plasmid production in different host strains of Escherichia coli.

Authors:  Adam Singer; Mark A Eiteman; Elliot Altman
Journal:  J Ind Microbiol Biotechnol       Date:  2009-01-10       Impact factor: 3.346

Review 5.  Microbial ribonucleases (RNases): production and application potential.

Authors:  E Esin Hameş; Tuğçe Demir
Journal:  World J Microbiol Biotechnol       Date:  2015-10-03       Impact factor: 3.312

6.  Enzymatically amplified linear dbDNATM as a rapid and scalable solution to industrial lentiviral vector manufacturing.

Authors:  Maria Barreira; Claire Kerridge; Sara Jorda; Didrik Olofsson; Alexander Neumann; Helen Horton; Sarah Smith-Moore
Journal:  Gene Ther       Date:  2022-05-24       Impact factor: 5.250

7.  Measuring Oligonucleotide Hydrolysis in Cellular Lysates via Viscosity Measurements.

Authors:  Romel Menacho-Melgar; Michael D Lynch
Journal:  Bio Protoc       Date:  2022-01-20

8.  Time-course determination of plasmid content in eukaryotic and prokaryotic cells using real-time PCR.

Authors:  Elisabete Carapuça; Adriano R Azzoni; Duarte M F Prazeres; Gabriel A Monteiro; Filipe J M Mergulhão
Journal:  Mol Biotechnol       Date:  2007-10       Impact factor: 2.695

9.  High frequency plasmid recombination mediated by 28 bp direct repeats.

Authors:  Sofia C Ribeiro; Pedro H Oliveira; Duarte M F Prazeres; Gabriel A Monteiro
Journal:  Mol Biotechnol       Date:  2008-07-08       Impact factor: 2.695

10.  Cultivation of E. coli carrying a plasmid-based Measles vaccine construct (4.2 kbp pcDNA3F) employing medium optimisation and pH-temperature induction techniques.

Authors:  Clarence M Ongkudon; Raelene Pickering; Diane Webster; Michael K Danquah
Journal:  Microb Cell Fact       Date:  2011-03-05       Impact factor: 5.328

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.